Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodeler) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer. This “Active Checkpoint Control Immunotherapy” activates all four naturally available tumour killing mechanisms of the immune system without triggering side effects. The company’s lead candidate OQR100 (TYG100), co-developed with TYG Oncology Ltd. and CR-UK, targets pancreatic cancer and induces neutralizing antibodies against gastrin, a major growth factor for pancreatic- and other forms of gastric cancer. OQR200 is directed against HER2/neu over-expressing breast cancer and induces strong polyclonal humoral (IgG and IgA) and cellular (CD4 and CD8) immune responses, superior to trastuzumab, pertuzumab or passive checkpoint inhibitors. Both lead candidates, which have achieved in vivo Proof of Concept in non-human primates, as well as the S-TIR™ technology platform are now available for out-licensing. For further information visit www.oncoqr.com. + Cancer immunotherapy + Active therapy (protein/peptide based) + Checkpoint Control + No side effects + Activation of all 4 naturally available killing mechanisms of the immune system + Multiple cancer targets